Eur. Urol.
Combining enzalutamide with abiraterone, prednisone, and androgen deprivation therapy in the STAMPEDE trial.
ABSTRACT
There are compelling reasons to study the addition of both enzalutamide and abiraterone, in combination, to standard-of-care for hormone-naïve prostate cancer. Through a protocol amendment, this will be assessed in the STAMPEDE trial, with overall survival as primary outcome measure.
Related Questions
Should it be started at the initial diagnosis of bone mets?
New comment by Medical Oncologist at Stephen B. Strum, MD PC ( September 5, 2018)
An MD cannot use any anti-resorptive agent rationally unless they understand the mechanism of action involved in excessive bone resorption. An activated osteoclast population...